Matrix Asset Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-163,338
| Closed | -$15.1M | – | 110 |
|
|
2024
Q4 | $15.1M | Sell |
163,338
-18,324
| -10% | -$1.65M | 1.65% | 27 |
|
|
2024
Q3 | $15.2M | Sell |
181,662
-1,615
| -0.9% | -$123K | 1.69% | 26 |
|
|
2024
Q2 | $12.6M | Sell |
183,277
-128,268
| -41% | -$8.56M | 1.5% | 31 |
|
|
2024
Q1 | $22.8M | Buy |
311,545
+14,200
| +5% | +$1.09M | 2.73% | 13 |
|
|
2023
Q4 | $24.1M | Sell |
297,345
-6,509
| -2% | -$507K | 3.07% | 12 |
|
|
2023
Q3 | $22.8M | Buy |
303,854
+3,123
| +1% | +$240K | 3.25% | 9 |
|
|
2023
Q2 | $23.2M | Sell |
300,731
-21,894
| -7% | -$1.75M | 3.19% | 8 |
|
|
2023
Q1 | $26.8M | Buy |
322,625
+5,753
| +2% | +$476K | 3.87% | 4 |
|
|
2022
Q4 | $27.2M | Sell |
316,872
-11,180
| -3% | -$885K | 4.08% | 3 |
|
|
2022
Q3 | $20.2M | Buy |
328,052
+161,043
| +96% | +$10.2M | 3.32% | 11 |
|
|
2022
Q2 | $10.3M | Sell |
167,009
-195,980
| -54% | -$12.1M | 1.59% | 30 |
|
|
2022
Q1 | $21.6M | Buy |
362,989
+33,818
| +10% | +$2.16M | 2.9% | 13 |
|
|
2021
Q4 | $23.9M | Sell |
329,171
-22,445
| -6% | -$1.55M | 3.11% | 11 |
|
|
2021
Q3 | $24.6M | Buy |
351,616
+1,632
| +0.5% | +$115K | 3.46% | 7 |
|
|
2021
Q2 | $24.1M | Sell |
349,984
-731
| -0.2% | -$48.8K | 3.46% | 7 |
|
|
2021
Q1 | $22.7M | Buy |
350,715
+50,430
| +17% | +$3.25M | 3.38% | 8 |
|
|
2020
Q4 | $17.5M | Buy |
300,285
+24,354
| +9% | +$1.47M | 2.95% | 9 |
|
|
2020
Q3 | $17.4M | Buy |
275,931
+23,702
| +9% | +$1.64M | 3.39% | 7 |
|
|
2020
Q2 | $19.4M | Sell |
252,229
-40,551
| -14% | -$3.11M | 3.72% | 7 |
|
|
2020
Q1 | $21.9M | Sell |
292,780
-30,646
| -9% | -$2.12M | 4.98% | 2 |
|
|
2019
Q4 | $21M | Buy |
323,426
+31,727
| +11% | +$2.07M | 3.43% | 8 |
|
|
2019
Q3 | $18.5M | Buy |
291,699
+13,080
| +5% | +$855K | 3.27% | 10 |
|
|
2019
Q2 | $18.8M | Sell |
278,619
-18,257
| -6% | -$1.2M | 3.34% | 8 |
|
|
2019
Q1 | $19.3M | Buy |
296,876
+15,036
| +5% | +$999K | 3.3% | 9 |
|
|
2018
Q4 | $17.6M | Buy |
281,840
+3,444
| +1% | +$241K | 3.27% | 10 |
|
|
2018
Q3 | $21.5M | Buy |
278,396
+9,074
| +3% | +$685K | 3.43% | 8 |
|
|
2018
Q2 | $19.1M | Buy |
269,322
+20,046
| +8% | +$1.42M | 3.15% | 8 |
|
|
2018
Q1 | $18.8M | Buy |
249,276
+9,561
| +4% | +$760K | 3.1% | 8 |
|
|
2017
Q4 | $17.2M | Buy |
239,715
+16,178
| +7% | +$1.23M | 2.73% | 12 |
|
|
2017
Q3 | $18.1M | Buy |
223,537
+27
| +0% | +$2.06K | 2.98% | 11 |
|
|
2017
Q2 | $15.8M | Buy |
223,510
+8,815
| +4% | +$587K | 2.71% | 12 |
|
|
2017
Q1 | $14.6M | Buy |
214,695
+16,632
| +8% | +$1.17M | 2.56% | 14 |
|
|
2016
Q4 | $14.2M | Buy |
198,063
+13,104
| +7% | +$974K | 2.4% | 14 |
|
|
2016
Q3 | $14.6M | Buy |
184,959
+29,174
| +19% | +$2.37M | 2.58% | 12 |
|
|
2016
Q2 | $13M | Buy |
155,785
+23,901
| +18% | +$2.12M | 2.53% | 14 |
|
|
2016
Q1 | $12.1M | Buy |
131,884
+10,643
| +9% | +$960K | 2.39% | 16 |
|
|
2015
Q4 | $12.3M | Sell |
121,241
-50,678
| -29% | -$5.27M | 2.36% | 17 |
|
|
2015
Q3 | $16.9M | Buy |
171,919
+7,340
| +4% | +$815K | 2.41% | 21 |
|
|
2015
Q2 | $19.3M | Sell |
164,579
-11,486
| -7% | -$1.26M | 2.42% | 23 |
|
|
2015
Q1 | $17.3M | Buy |
176,065
+119,166
| +209% | +$12.1M | 2% | 29 |
|
|
2014
Q4 | $5.36M | Buy |
56,899
+13,793
| +32% | +$1.43M | 0.61% | 36 |
|
|
2014
Q3 | $4.59M | Buy |
43,106
+250
| +0.6% | +$24.5K | 0.53% | 38 |
|
|
2014
Q2 | $3.55M | Buy |
+42,856
| New | +$3.34M | 0.4% | 45 |
|
Other funds holding GILD
Matrix Asset Advisors's GILD Position: Q1 2025 in Review
Matrix Asset Advisors sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 163,338 shares — an estimated $15.1M sold.
Matrix Asset Advisors first reported a position in GILD in Q2 2014 and held it in 43 quarters. The position peaked at $27.2M in Q4 2022. 2,012 funds tracked by Wall St. Rank hold GILD as of Q1 2025.
- Matrix Asset Advisors reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
- Matrix Asset Advisors sold 163,338 Gilead Sciences shares in Q1 2025, an estimated $15.1M.
- Matrix Asset Advisors first reported a position in Gilead Sciences in Q2 2014 and held it in 43 quarters.
- Matrix Asset Advisors's Gilead Sciences position peaked at $27.2M in Q4 2022.
- 2,012 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.
Based on Matrix Asset Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.